June 17th 2023
Antimicrobial resistance is resistance to multiple classes of antibiotics, which makes it extremely challenging to treat infections caused by such organisms.
November 14th 2022
The Ins and Outs of Lubricating Eye Drops
View More
What’s New in MGD Beyond Heating and Squeezing?
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Community Practice Connections™: Expert Perspectives in Diabetic Macular Edema – Considering Pathogenesis & Inflammation in Treatment Selection
View More
Modern-izing Retina
September 4 - 5, 2024
View More
Medical Crossfire®: Expert Insights in Anti-VEGF Dosing for nAMD and DME – Optimizing Reduction in Treatment Burden
View More
Medical Crossfire®: Considerations for the Use of Biosimilars in Retinal Disease - Are You Prepared for a New Paradigm? (CME Credit)
View More
Community Practice Connections™: Novel Treatment Strategies in the Management of nAMD & DME - Lessons from Clinical Trial and Real-World Data
View More
Medical Crossfire®: Considerations for the Use of Biosimilars in Retinal Disease - Are You Prepared for a New Paradigm? (COPE Credit)
View More
EyeCon 2024
September 27-28, 2024
Register Now!
Join us after AAO for a CME session | In-Person + Virtual
October 19, 2024
Register Now!
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (COPE Credit)
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (CME/CNE Credit)
View More
(COPE) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Advancing Treatment in Neovascular Retinal Disease with Novel Therapies: Insights and Strategies from Latest Real-World and Clinical Data
View More
Rapid Reviews in Retina™: Emerging Updates from Fall 2023 – Addressing the Wealth of New Data in Treatments for nAMD and DME
View More
(CME) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(CME) Stratifying the Spectrum of Care in Glaucoma Management – Advancing Treatment with a Vast Armamentarium
View More
(COPE) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(COPE) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
(CME) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
(COPE) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
(CME) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (COPE Credit)
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (CME Credit)
View More
SimulatED™: Applying Advanced Treatment for nAMD & DME - Simulating New Strategies for Clinical Management
View More
Navigating the Advances in the Treatment of Geographic Atrophy: Updates and Strategies for Managed Care
View More
Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (CME Track)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)
View More
Universal masking may lower risk of endophthalmitis after intravitreal anti-VEGF injections
October 10th 2021During the ASRS Annual Scientific Meeting, Dr Sunir Garg reported that the risk of presumed infectious endophthalmitis following administration of anti-VEGF injections does not increase and universal masking may actually decrease the risk of culture-positive endophthalmitis.
The relationship between MIGS procedures and endophthalmitis
October 10th 2021At the ASRS 39th Annual Scientific Meeting, Dr Yoshihiro Yonekawa reported that the prevalence of endophthalmitis following MIGS is similar to the prevalence rates of endophthalmitis after other incisional glaucoma surgeries.
Autoimmune uveitis targeted by AAV gene therapy
September 8th 2021Investigators have found that 1 intravitreal injection of an adeno-associated virus encoding an immunosuppressive transgene, either HLA-G or eqIL-10, reduced the clinical and histologic inflammation in a well-established model of autoimmune uveitis.
Considering antibiotics use in postoperative endophthalmitis
June 1st 2021Whilst endophthalmitis following cataract surgery can lead to serious vision outcomes, there are ways of minimising the risk of it occurring whilst also being mindful of the need to prescribe antibiotics in a way that does not worsen antimicrobial resistance.
Navigating COVID-19 with ophthalmic patients in the hospital setting
February 22nd 2021Experience at one ophthalmic practice in Bulgaria demonstrates that new operating procedures, technologies and good management can enable clinics to remain open and operate safely during the COVID-19 pandemic. Ophthalmic training and education should continue to be a priority.
COVID-19 presents opportunities for new directions in ophthalmology
November 13th 2020COVID-19 has had a significant impact on the entire global community. As we look to the future to advance the provision of eyecare excellence, opportunities for innovation must be embraced and new, patient-centric ways of managing clinical practices adopted.
Maintaining quality and safety in retina clinics during a pandemic
October 7th 2020To maintain treatment quality and patient and staff safety in the SARS-CoV-2 era, it is important to minimise clinic visits and maximise use of imaging modalities. In addition, extending treatment intervals with longer-acting agents is key to maximising safety and patients’ vision outcomes.
Endophthalmitis most often caused by Staphylococcus
April 17th 2014Endophthalmitis is most often caused by coagulase-negative Staphylococcus, and the antibiotics vancomycin and ceftazidime seem to perform well in treating it. That was one of the findings of a 25-year retrospective study conducted by Dr Ronald C. Gentile, of the New York Eye and Ear Infirmary, and his colleagues in New York City and San Antonio, Texas, USA.
Higher temperatures linked to severity of allergic conjunctivitis
March 14th 2014Temperatures measured by a newly developed non-contact ocular surface thermographer (OST) can be used to evaluate the efficacy of topical anti-allergic agents because of the significant correlation of the conjunctival surface temperature and the severity of conjunctival allergic reaction, according to recently published data.
Point of care tear film test simplifies dry eye management
October 1st 2009Diagnosing and managing dry eye patients can be challenging. Here Dr Philipp Steven looks at a new way of treating tear film osmolarity, the TearLab Osmolarity System, which he believes could dramatically simplify the process.
Clinical improvement in adenoviral conjunctivitis model
July 15th 2009Foresight Biotherapeutics, Inc. has announced data from a pre-clinical study designed to assess the safety and efficacy of the topical administration of FST-100 in a highly regarded Ad5 NZW rabbit model of adenoviral conjunctivitis.
Novagali technologies allow greater drug access to the posterior of the eye
March 25th 2009According to research analysts it is estimated that as little as five percent of a topically applied drug ever reaches the intraocular tissues due to drug loss as the result of tearing, lacrimal fluid-eye barriers, and blood-ocular barriers.